US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Glaukos Corporation Common Stock (NY:GKOS)

164.84 -0.76 (-0.46%)
Official Closing Price Updated: 7:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Glaukos Announces the Release of its 2020 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
Why Glaukos's Stock is Up During Today's Session ↗
Glaukos's Stock Price And Volume Action Glaukos (NYSE:GKOS) is curre... 
Via Benzinga
News headline image
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
From Glaukos Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021 ↗
Upgrades According to Oppenheimer, the prior rating for Glaukos Corp (NYSE:GKOS) was changed from Perform to Outperform. Glaukos earned $0.02 in the fourth quarter,... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >